Business Wire

FERRING-PHARMACEUTICALS

Share
Ferring and Igenomix Collaborate to Advance Care in Reproductive Medicine and Maternal Health

Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005784/en/

A new research hub will be created in Boston, bringing together scientists and expertise from both companies. The hub will focus on investigating molecular signatures, developing novel functional genomic systems and creating translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology to drive innovative solutions for patients.

“Today, 1 in 6 couples worldwide are affected by fertility issues, with embryo implantation being a critical step to improving success rates in assisted reproduction technologies (ART) such as IVF. Furthermore, between 3 and 5% of all pregnancies are affected by preeclampsia,1 a severe complication which increases the morbidity and mortality of both mother and baby, said Joan-Carles Arce, Senior Vice President of Reproductive Medicine and Maternal Health, Ferring. Through this collaboration, we aim to advance diagnostic testing and the discovery of candidate drug targets in these areas of high unmet need and ultimately help more people build healthy families worldwide.”

“This new research hub will connect Igenomix’s unique diagnostic capabilities with Ferring’s deep therapeutic expertise, said Professor Carlos Simón, Head of Scientific Board of Igenomix Foundation and Project Lead for the new hub. We believe this collaboration will accelerate scientific findings and improve conception rates at a time when significant progress is needed in preimplantation science to help more women and families experience healthy pregnancies.”

ENDS

About Fertility Issues

The World Health Organization defines infertility as a disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. Today, 1 in 6 couples worldwide are affected by fertility issues. Assisted Reproductive Technologies (ART) such as In Vitro Fertilisation (IVF) and Intracytoplasmic Sperm Injection (ICSI) can help couples who have problems conceiving naturally.

About Preeclampsia

Preeclampsia is a common and severe complication of pregnancy characterised by high blood pressure and multiple organ failure. It affects between 3% and 5% of all pregnancies in the US.1 There is a significant unmet need for an effective treatment for preeclampsia; currently the only ‘treatment’ is delivery of the baby.

Preeclampsia is responsible for approximately 20% of all preterm births2 and increases the morbidity and mortality of both mother and baby, especially in developing countries. An effective treatment would bring significant improvements in global infant and maternal health.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com , or connect with us on Twitter , Facebook , Instagram , LinkedIn and YouTube .

About Igenomix

Igenomix is a biotech company based in Valencia, Spain, specialized in reproductive genetics. Its expertise in fertility and its advanced research capacity situates the company as a worldwide referent in this area. Igenomix has 23 laboratories across the world and employs more than 400 professionals. Since the company launch in 2010, Igenomix has published more than 450 scientific papers and its communications have taken place during high level congresses such as ESHRE (European Society of Human Reproduction) or ASRM (American Society for Reproductive Medicine). Igenomix researchers have received numerous awards recognizing research and many of them share their knowledge and knowhow in leading US universities such as Stanford or Harvard.

References:

  1. CDC High Blood Pressure During Pregnancy 2020. Available at: https://www.cdc.gov/bloodpressure/pregnancy.htm
  2. Preeclampsia Foundation. FAQs. 2018. Available at: https://www.preeclampsia.org/faqs

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Launches 7th Edition of Good Food Makers to Shape the Future of Food2.7.2025 14:20:00 CEST | Press release

Barilla officially opens applications for Good Food Makers 2025, its open innovation program dedicated to startups and innovative companies focused on creating a more sustainable and connected food system. Now in its seventh edition, the program welcomes a new format — Good Food Makers – ECOSYSTEM — developed in collaboration with Almacube, the innovation hub of the University of Bologna and Confindustria Emilia. This year’s goal is to build a true innovation ecosystem by involving Barilla’s value chain partners and accelerating the adoption of emerging technologies. Three selected startups will join a four-week co-development journey with Barilla professionals and partner companies, working side-by-side to create impactful solutions across the entire food chain — from field to fork. Applications are open until the end of July, with the program running from September to January 2026, concluding with the Innovation Day. “Good Food Makers reflects our commitment to open innovation that g

SE Labs Award Reinforces NetApp Status as the Most Secure Storage on the Planet2.7.2025 14:00:00 CEST | Press release

NetApp wins 2025 SE Labs Award for Enterprise Data Protection NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it was recognized as a standout performer in cybersecurity in the SE LABS ® Awards 2025. NetApp won the 2025 SE Labs Award for Enterprise Data Protection, validating NetApp’s status as the most secure storage on the planet. This recognition as a winner of a 2025 SE Labs Award is a result of NetApp’s exceptional innovation in cyber resiliency to deliver NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI), which was tested and validated by SE Labs. NetApp ARP/AI demonstrated 99 percent detection of tested, advanced full-file encryption ransomware attacks with zero false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue. “Great security doesn’t just happen—it’s built, tested and proven,” says Simon Edwards, Founder and CEO of SE Labs. “Behind every

CroíValve Announces Funding from Horizon Europe EIC Accelerator2.7.2025 14:00:00 CEST | Press release

CroíValve, a pioneering medical device company innovating a better way to help more patients suffering from Tricuspid Regurgitation (TR), was awarded funding from Horizon Europe’s European Innovation Council (EIC) Accelerator Programme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702306192/en/ DUO™ Transcatheter Tricuspid System Part of the EU’s Horizon Europe 2021-2027 Research and Innovation Programme, the EIC Accelerator Programme provides transformational funding to high-potential, high-risk start-ups, scale-ups and subject matter experts. This award includes grant funding of €2.5 million, combined with an equity investment of €10 million in CroiValve’s next financing. The latest competition included 959 applications, with only 40 awards across 16 countries. Almost one third of the selected companies are led by a woman and CroiValve are incredibly proud to be one of this group. “Securing European Innovation Council

EUMETSAT: Europe’s First Geostationary Sounder Satellite Is Launched2.7.2025 13:20:00 CEST | Press release

Europe has taken a major step forward in strengthening its resilience to extreme weather events with the successful launch of the Meteosat Third Generation Sounder 1 (MTG-S1) satellite. MTG-S1 will deliver new streams of atmospheric data, enabling earlier, more accurate warnings that protect lives, property and infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702002782/en/ MTG-S1 is part of the Meteosat Third Generation programme, Europe’s new fleet of geostationary meteorological satellites. Image: EUMETSAT Extreme weather events like storms, flooding, and heatwaves have caused hundreds of billions of euros in damage and claimed tens of thousands of lives across Europe in the past decades. Launched on 1 July 2025, MTG-S1 will provide Europe’s national meteorological services with high-frequency data on temperature, humidity and trace gases throughout the atmosphere – enabling forecasters to detect the earli

HCLTech and Equinor Expand Digital Collaboration2.7.2025 13:08:00 CEST | Press release

HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye